CN108865147B - 一种埃罗替尼保护的铂银纳米簇及其制备方法 - Google Patents
一种埃罗替尼保护的铂银纳米簇及其制备方法 Download PDFInfo
- Publication number
- CN108865147B CN108865147B CN201810554375.0A CN201810554375A CN108865147B CN 108865147 B CN108865147 B CN 108865147B CN 201810554375 A CN201810554375 A CN 201810554375A CN 108865147 B CN108865147 B CN 108865147B
- Authority
- CN
- China
- Prior art keywords
- erlotinib
- silver
- platinum
- alkyne
- nanocluster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- GNLCAVBZUNZENF-UHFFFAOYSA-N platinum silver Chemical compound [Ag].[Ag].[Ag].[Pt] GNLCAVBZUNZENF-UHFFFAOYSA-N 0.000 title claims abstract 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 20
- 229960001433 erlotinib Drugs 0.000 claims abstract description 19
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004020 luminiscence type Methods 0.000 claims abstract description 10
- -1 platinum silver alkyne Chemical class 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920000642 polymer Polymers 0.000 claims abstract description 4
- 239000012279 sodium borohydride Substances 0.000 claims abstract description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims abstract description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 3
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 3
- 239000002243 precursor Substances 0.000 claims abstract description 3
- 229910052709 silver Inorganic materials 0.000 claims description 8
- 239000004332 silver Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical group C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 238000005415 bioluminescence Methods 0.000 abstract description 3
- 230000029918 bioluminescence Effects 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 239000002159 nanocrystal Substances 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 230000000007 visual effect Effects 0.000 abstract description 2
- HTYPUNPKBFMFFO-UHFFFAOYSA-N platinum silver Chemical compound [Ag][Pt][Pt] HTYPUNPKBFMFFO-UHFFFAOYSA-N 0.000 description 14
- 239000003446 ligand Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 7
- 229910000510 noble metal Inorganic materials 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000010970 precious metal Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001941 electron spectroscopy Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/87—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing platina group metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/185—Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd
Abstract
本发明公开了一种埃罗替尼保护的铂银纳米簇及其制备方法。利用埃罗替尼炔银聚合物[Ag(Erlotinib)]n和Pt(tht)2Cl2作为前驱体，CH2Cl2和甲醇作反应溶剂，在绝氧的条件下室温中搅拌反应2h后，用NaBH4为还原剂，绝氧且室温下搅拌反应24h，利用氯仿和乙醚重结晶，合成得到埃罗替尼保护的铂银炔纳米簇[PtAg12(Erlotinib)8]Cl6。本方法工艺简单，反应条件温和，产率高；发明的铂银炔纳米簇结构独特，纳米晶体粒径小（约2 nm左右），具有在可见光区和近红外光区具有双重发光性质，在癌症的可视化治疗和近红外生物发光传感方面都具有巨大潜在的应用。
Description
技术领域
本发明属于发光传感生物分析技术领域，具体涉及一种埃罗替尼保护的铂银纳米簇及其制备方法。
背景技术
贵金属纳米簇是指在一定分子层的保护下，由几个到几百个半径小于其电子费米波长的金、银和铂等金属原子构成的分子聚集体。贵金属纳米簇不仅具有好的光稳定性、大的斯托捷克位移、发射波长在可见与近红外区域内可控、双光子吸收特性等更优异的光学性质，而且具有毒性更小、尺寸更小，且不易发生自聚等优点，使其在发光传感生物医药分析方面具有极大的应用前景，正成为化学、生物和医药等众多领域研究的热点。现有已公开发表的贵金属纳米簇合物的保护配体多数为巯基小分子配体和有机膦配体，结构比较单一，而且大部分的巯基小分子配体和有机膦配体保护的贵金属纳米簇往往表现出较差的发光性能和对生物样品特异性识别能力不强的缺点，限制了其在在发光传感生物分析方面的广泛应用。近年来，研究表明有机炔配体(-C≡CR)是构建精确原子结构的发光贵金属纳米簇的理想表面配体，在发光传感生物医药分析方面具有极大的潜在应用前景。然而该研究才刚刚起步，仅处于个例合成和结构表征、性能研究的初步阶段，缺少发光功能导向的结构设计，尤其是针对其在发光传感生物医药分析应用领域的设计研究几乎处于空白。
发明内容
本发明的目的在于针对现有技术的不足，提供一种埃罗替尼保护的铂银纳米簇及其制备方法。本发明所制备的铂银炔纳米簇结构独特，纳米晶体粒径小（约2 nm左右），具有优良的发光性能，在可见光区和近红外光区具有双重发光性质。
为实现本发明的目的，采用如下技术方案：
本发明所选用的埃罗替尼（C22H23N3O4）配体是一种受体酪氨酸酶抑制药物，可用于局部晚期或转移的非小细胞肺癌的二线治疗，生物兼容性和毒性小；而且它具有炔键，可以与贵金属铂和银离子以不同的方式配位，有利于提高银纳米簇的稳定性和发光性能。
本发明通过一步化学反应合成得到一种埃罗替尼保护的铂银纳米簇[PtAg12(Erlotinib)8]Cl6（合成路线如附图1所示）。所述目标铂银纳米簇的合成是利用埃罗替尼炔银聚合物[Ag(Erlotinib)]n和Pt(tht)2Cl2（tht=四氢噻吩）作为前驱体，CH2Cl2和甲醇混合溶剂作反应溶剂，在绝氧的条件下室温中搅拌反应2h后，用NaBH4为还原剂，绝氧且室温下搅拌反应24h，利用氯仿和乙醚重结晶，合成得到一种埃罗替尼保护的铂银炔纳米簇[PtAg12(Erlotinib)8]Cl6。
本方法工艺简单，反应条件温和，产率高；发明的铂银炔纳米簇结构独特，纳米晶体粒径小（约2 nm左右），具有优良的发光性能，在可见区（492 nm）和近红外区（982 nm）具有双重发光，在制备癌症可视化治疗药物中和近红外生物发光传感方面都具有巨大潜在的应用。制备成本低，没有有害废弃物产生，符合“绿色生产”的要求。
更具体的制备方法为：
将0.1 mmol 的Pt(tht)2Cl2和0.8 mmol [Ag(Erlotinib)]n混合溶于6 mL的二氯甲烷和3 mL的甲醇混合溶液中，在绝氧的条件下室温搅拌反应2小时得到黄色的澄清溶液，之后再逐滴加入0.2 mmol的NaBH4的甲醇溶液，溶液由黄色澄清变成红褐色的浑浊，绝氧且室温下搅拌反应24小时待反应结束后旋干，将用二氯甲烷溶解，离心，溶于二氯甲烷部分旋干，用乙醚多次洗涤后，用氯仿-乙醚重结晶，即得到红褐色的铂银纳米簇[PtAg12(Erlotinib)8]Cl6。
本发明的有益效果在于：
1）本发明所合成的铂银纳米簇[PtAg12(Erlotinib)8]Cl6受到埃罗替尼配体的保护，而埃罗替尼配体是一种受体酪氨酸酶抑制药物，可用于局部晚期或转移的非小细胞肺癌的二线治疗；而且它具有炔键，可以与贵金属铂和银离子以不同的方式配位，有利于提高银纳米簇的稳定性和发光性能；
2）本发明制备方法工艺简单，反应条件温和，产率高；所制备的铂银纳米簇为球形结构，纳米粒径小，约2 nm左右，具有优良的发光性能，在可见区（492 nm）和近红外区（982nm）具有双重性质；
3）本发明的铂银纳米簇可望解决异金属纳米簇发光传感器在实际分析测定特定生物样品应用中的生物兼容性、选择性、靶向性和灵敏度等问题，在癌症的可视化治疗和近红外生物发光传感方面都具有巨大潜在的应用。
附图说明
图1是铂银纳米簇的合成路线图（已略去配体）；
图2是铂银纳米簇的TEM和HRTEM；
图3是铂银纳米簇在二氯甲烷中的紫外-可见吸收光谱(A)和发射光谱(B，C)。
具体实施方式
为进一步公开而不是限制本发明，以下结合实例对本发明作进一步的详细说明。
实施例1
将0.1 mmol 的Pt(tht)2Cl2和0.8 mmol [Ag(Erlotinib)]n混合溶于6 mL的二氯甲烷和3 mL的甲醇混合溶剂中，在绝氧的条件下室温搅拌反应2小时得到黄色的澄清溶液，之后再逐滴加入0.2 mmol的NaBH4的甲醇溶液，溶液由黄色澄清变成红褐色的浑浊，绝氧且室温下搅拌反应24小时待反应结束后旋干，将用二氯甲烷溶解，离心，溶于二氯甲烷部分旋干，用乙醚多次洗涤后，用氯仿-乙醚重结晶，即得到红褐色的铂银纳米簇[PtAg12(Erlotinib)8]Cl6。
纳米簇[PtAg12(Erlotinib)8]Cl6的化学式：PtAg12C176H176N24O32Cl6。
元素分析[理论值 (实验值) (%)]：C：43.66 (41.81)；H：3.66 (4.05)；N：6.94(6.91)。
ICP分析[理论值 (实验值) (%)]：Pt：4.03 (3.94)；Ag：26.73 (26.77)；(Pt:Ag =1:12摩尔比)。
红外吸收主要特征峰 (KBr，ν / cm-1) : 2106，2051 (w，C≡C)。
电子能谱分析(XPS)：Ag 3d5/2 367.2，Ag 3d3/2 373.2 eV；Pt 4f7/2 71.8 eV，Pt4f5/2 75.2 eV。
核磁氢谱1H NMR (400 MHz，CD2Cl2，ppm)：δ 8.56 (s, 8H), 7.97 (s, 8H), 7.78(d, J = 4 Hz, 8H), 7.42-7.34 (m, 24H), 7.21 (s, 8H), 4.36 (s, 16H), 4.23(s,16H), 3.89 (s, 16H), 3.79 (s, 16H), 3.50 (d, 3H), 3.45 (s, 3H), 3.21( s, 8H)。
产品的使用过程和方式：该新型的铂银纳米簇[PtAg12(Erlotinib)8]Cl6在氧气存在下稳定性好，可在空气中长时间保存。
以上所述仅为本发明的较佳实施例，凡依本发明申请专利范围所做的均等变化与修饰，皆应属本发明的涵盖范围。
Claims (1)
1.一种埃罗替尼保护的铂银纳米簇的制备方法，其特征在于：其分子式为：[PtAg12(Erlotinib)8]Cl6；所述的铂银纳米簇为球形结构，纳米粒径为0.6-2.0 nm，在可见光区和近红外光区具有双重发光性质；
所述制备方法为：以埃罗替尼炔银聚合物和Pt(tht)2Cl2作为前驱体，以CH2Cl2和甲醇混合溶剂为反应溶剂，在绝氧的条件下室温中搅拌反应2h后，加入还原剂NaBH4，绝氧且室温下搅拌反应24h，利用氯仿和乙醚重结晶，合成得到埃罗替尼保护的铂银纳米簇[PtAg12(Erlotinib)8]Cl6；其中Pt(tht)2Cl2、埃罗替尼炔银聚合物和NaBH4的摩尔比为1:8:2；CH2Cl2和甲醇混合溶剂中，CH2Cl2和甲醇的体积比为2:1；上述Pt(tht)2Cl2中tht=四氢噻吩。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554375.0A CN108865147B (zh) | 2018-06-01 | 2018-06-01 | 一种埃罗替尼保护的铂银纳米簇及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554375.0A CN108865147B (zh) | 2018-06-01 | 2018-06-01 | 一种埃罗替尼保护的铂银纳米簇及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108865147A CN108865147A (zh) | 2018-11-23 |
| CN108865147B true CN108865147B (zh) | 2021-05-18 |
Family
ID=64336249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810554375.0A Expired - Fee Related CN108865147B (zh) | 2018-06-01 | 2018-06-01 | 一种埃罗替尼保护的铂银纳米簇及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108865147B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478402B (zh) * | 2021-12-29 | 2023-09-05 | 福州大学 | 一种光诱导合成近红外发光的埃罗替尼银纳米团簇及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083687A (zh) * | 2013-01-16 | 2013-05-08 | 东南大学 | 一种银、铂纳米簇在肿瘤靶向成像的应用 |
| CN103357886A (zh) * | 2013-06-28 | 2013-10-23 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种用于荧光传感器的贵金属纳米团簇的制备方法 |
| CN105784616A (zh) * | 2016-04-08 | 2016-07-20 | 江南大学 | 基于双金属纳米团簇检测半胱氨酸或乙酰半胱氨酸的方法 |
| CN105855565A (zh) * | 2016-06-20 | 2016-08-17 | 福建农林大学 | 基于三倍体dna为模板的银铂双金属纳米簇及其合成方法 |
| CN106413738A (zh) * | 2014-01-17 | 2017-02-15 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| CN107652311A (zh) * | 2017-10-26 | 2018-02-02 | 福州大学 | 一种有机膦铜纳米簇合物晶体及其制备方法 |
-
2018
- 2018-06-01 CN CN201810554375.0A patent/CN108865147B/zh not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083687A (zh) * | 2013-01-16 | 2013-05-08 | 东南大学 | 一种银、铂纳米簇在肿瘤靶向成像的应用 |
| CN103357886A (zh) * | 2013-06-28 | 2013-10-23 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种用于荧光传感器的贵金属纳米团簇的制备方法 |
| CN106413738A (zh) * | 2014-01-17 | 2017-02-15 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| CN105784616A (zh) * | 2016-04-08 | 2016-07-20 | 江南大学 | 基于双金属纳米团簇检测半胱氨酸或乙酰半胱氨酸的方法 |
| CN105855565A (zh) * | 2016-06-20 | 2016-08-17 | 福建农林大学 | 基于三倍体dna为模板的银铂双金属纳米簇及其合成方法 |
| CN107652311A (zh) * | 2017-10-26 | 2018-02-02 | 福州大学 | 一种有机膦铜纳米簇合物晶体及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 林志香等.炔基保护下的铂银纳米簇的合成及性能研究.《中国化学会第八届全国配位化学会议论文集》.2017, * |
| 炔基保护下的铂银纳米簇的合成及性能研究;林志香等;《中国化学会第八届全国配位化学会议论文集》;20170719;第1页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108865147A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112079684B (zh) | 具有聚集诱导发光效应的柱芳烃及类柱芳烃化合物及其制备方法与应用 | |
| CN110294777B (zh) | 一种含磷树冠大分子基杂化纳米材料及其制备方法和应用 | |
| CN107652311B (zh) | 一种有机膦铜纳米簇合物晶体及其制备方法 | |
| Meng et al. | Controlled reduction for size selective synthesis of thiolate-protected gold nanoclusters Au n (n= 20, 24, 39, 40) | |
| Ranjbar et al. | Sonochemical synthesis of a novel nano-rod two-dimensional zinc (II) coordination polymer; preparation of zinc (II) oxide nanoparticles by direct thermolyses | |
| CN101353357A (zh) | 一种有机锡化合物及其制备方法与应用 | |
| CN108865147B (zh) | 一种埃罗替尼保护的铂银纳米簇及其制备方法 | |
| Benetollo et al. | Synthesis, characterization and hydrolytic behavior of new bis (2-pyridylthio) acetate ligand and related organotin (IV) complexes | |
| Jin et al. | Ultrasonic effect on RuO2 nanostructures prepared by direct calcination of two new Ru (II)-organic supramolecular polymers | |
| Rodrigues et al. | Au (I) N-heterocyclic carbenes from bis-imidazolium amphiphiles: synthesis, cytotoxicity and incorporation onto gold nanoparticles | |
| CN107501372A (zh) | 手性氮杂环卡宾金化合物及其制备方法和用途 | |
| CN115057893B (zh) | 一种三明治构型的靶向线粒体的有机金属铱配合物及其制备方法、应用 | |
| CN102731562A (zh) | 一种三苯基锡配位化合物及其制备方法与应用 | |
| CN113718338B (zh) | 一种硫杂杯[4]芳烃保护的炔银簇材料及其制备方法和应用 | |
| CN113336798B (zh) | 一种基于三均嗪的三核铂配合物及其制备方法和应用 | |
| Tanase et al. | Synthesis and characterization of gold (I) complexes with a triphosphine ligand having a bent trinuclear core interacted with a halide anion | |
| Li et al. | Assembly of molecular squares and helical chain polymers of Mo (W)/Cu/S clusters using thiolato ligands as linkers | |
| CN110496971B (zh) | Au34(SR)19金属纳米簇及其制备方法 | |
| Dou et al. | Synthesis, electrochemical properties and fungicidal activity of 1, 1′‐bis (aroyl) ferrocenes and their derivatives | |
| Liu et al. | Synthesis and cancer cell cytotoxicity of gold (III) tetraarylporphyrins with a C5-carboxylate substituent | |
| CN116199899B (zh) | 一类基于吡唑类有机配体的近红外、纳米金属有机框架材料及其制备方法 | |
| Ruiz et al. | Iron (III) oxamato-catalyzed epoxidation of alkenes by dioxygen and pivalaldehyde | |
| Liu et al. | Antitumor Platinum (II) Compounds of a Chiral Diamine with Functionalized Cyclobutane-1, 1-Dicarboxylates as Leaving Ligands | |
| CN114478402B (zh) | 一种光诱导合成近红外发光的埃罗替尼银纳米团簇及其制备方法 | |
| Pellei et al. | New triorganotin (IV) complexes of a polyfunctional S, N, O-ligand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210518 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |